▎WuXi AppTec Content Team Report

November 1 news: Baixi Ousi (Biocells) announced the completion of a multi-million RMB B+ round of financing, led byPine CapitalLead investment,Xiamen High-Tech InvestmentAndSaint诺 BiotechFollow-on Investment, Original ShareholderSaisun PharmaceuticalContinue to invest. According to the press release from Baixi Ousi, the funds raised in this round of financing will be used to advanceClass 1 Innovative Drug for Treating Ischemic StrokeBXOS110 Enters Phase 2 Clinical Trials,For neural repair and regeneration during the recovery phase of strokeBaixi Ousi (Beijing) Biological Technology Co., Ltd.'s two Class 1 innovative drug products, BXOS116 and BXOS401, have applied for IND.

Baixi Ousi is an innovative pharmaceutical company focused on the field of neurological diseases, concentrating onPrevention and Treatment of Neurological Damage Throughout the Entire Stroke Cycle, Neuroprotection in Ischemic and Hemorrhagic Strokes, Brain Edema, and Neural Repair, etc., the fields involved have significant unmet clinical needs.

Stroke has now become an important cause of death among Chinese citizens. Among them, ischemic stroke is caused by the blockage of cerebral blood vessels, leading to the interruption of blood supply, oxygen, and nutrients to brain tissue, which in turn causes irreversible damage to the brain tissue. This also leads to a series of cognitive, motor, and emotional disorders in patients, seriously affecting their quality of life and imposing a huge burden on society and families.

At the onset of ischemic stroke, tissue plasminogen activator should be administered immediately.Thrombolytic Therapy, restoring blood flow to the brain by reopening blocked vessels is the primary treatment option. However, due to the irreversible nature of nerve cell death, many patients, even after undergoing thrombolytic therapy, often suffer from severe "sequelae" such as aphasia and hemiplegia, significantly impacting the quality of life for both patients and their families. Following the occurrence of ischemic stroke,Protecting Damaged Nerve CellsIt can delay the irreversible death of nerve cells caused by it, while reducing reperfusion injury after thrombolysis, thereby improving the therapeutic effect.

Baixi Ousi PipelineNeuroprotective Agents for Acute Ischemic StrokeThat is a new, effective, and safe neuroprotective agent. The product has currently entered phase 2 clinical trials, conducted by Beijing Tiantan Hospital, affiliated with Capital Medical University.Dean Wang YongjunServe as the principal investigator. In addition, the company has multiple pipelines in reserve.Stroke and Brain Edema Treatment FieldThe product pipeline can successively submit IND applications.

Chairman of Baixi OusiTian QiupingExpressed: "We are very grateful for the joining of new shareholders such as PineWood Capital, Xiamen High-Tech, Saisun Pharmaceutical, and Sinuo Biotech at this critical moment, as well as the continued support from existing shareholders. We will continue to carry out the milestone Phase 2 clinical trial of BXOS110."BXOS110 is the company's first Class 1 innovative drug to enter clinical trials, aimed at neuroprotection during the ultra-acute phase of acute stroke; meanwhile, we will also actively advance the clinical translation of BXOS116 and BXOS401 for neural repair and regeneration during the stroke recovery phase, achieving a pipeline layout covering the entire disease cycle of stroke.Bureau,"To develop innovative drugs with genuine efficacy that address unmet clinical needs in the field of stroke. Pine Capital is a well-known investment institution with extensive experience in biopharmaceutical investments, and its participation has provided both financial support and professional assistance for the company's rapid and healthy development."